A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

Eligibility Criteria

• * Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.
• * Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.
• * Have adequate literacy, vision, and hearing for neuropsychological testing at screening.
• * Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.
• * Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.
• * If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening.
• * Have dementia or significant other neurological disease that can affect cognition.
• * Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.
• * Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.
• * Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.
• * Have a clinically important laboratory test result or other abnormality as determined by investigator that could be detrimental to the participant or could compromise the study.
• * Have any contraindications for magnetic resonance imaging (MRI).
• * Have a centrally read MRI demonstrating presence of ARIA-E, \>4 cerebral microhemorrhages, any superficial siderosis, any macrohemorrhage, or severe white matter disease at screening.
• * Have had prior treatment with a passive anti-amyloid immunotherapy within \<5 half-lives prior to screening.
• * Have received active immunization against Aβ in any other study.